We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
RSLS | ReShape Lifesciences Inc | 0.3333 | 0.1233 | 58.71% | 10,223,988 |
LUXH | LuxUrban Hotels Inc | 0.3895 | 0.0555 | 16.62% | 4,046 |
DRMA | Dermata Therapeutics Inc | 3.70 | 0.43 | 13.15% | 309 |
CCG | Cheche Group Inc | 1.48 | 0.16 | 12.12% | 5,296 |
AZ | A2Z Smart Technologies Corporation | 0.46 | 0.0398 | 9.47% | 233,983 |
BWAQ | Blue World Acquisition Corporation | 9.40 | 0.79 | 9.18% | 4,744 |
IKNA | Ikena Oncology Inc | 1.45 | 0.12 | 9.02% | 393 |
JZXN | Jiuzi Holdings Inc | 0.36 | 0.0278 | 8.37% | 209 |
NITO | N2OFF Inc | 0.9134 | 0.0634 | 7.46% | 327 |
VIVK | Vivakor Inc | 1.42 | 0.09 | 6.77% | 128 |
PPBT | Purple Biotech Ltd | 0.8165 | 0.0515 | 6.73% | 1,014 |
TORONTO, May 28, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company has successfully transformed into a high-innovation and high growth company.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences...
Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior"NRX-101 demonstrated a similar antidepressant effect (MADRS reduction ~50%) compared to lurasidone, the Standard of Care drugNRX-101 demonstrated a 58% relative reduction in time to sustained remission from suicidality (P=.05) compared to lurasidoneNRX-101 demonstrated a 76% reduction in symptoms of akathisia (p=0.03), a side effect linked to suicide, compared to lurasidoneThis represents the second trial of NRX-101 demonstrating reduction in suicidality and akathisia associated with NRX-101 compared to lurasidoneRADNOR, Pa., May 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, ...
Fourth Quarter Revenue Totaled $112.2 Million and Fiscal 2024 Revenue Totaled $544.5 Million Fourth Quarter GAAP Net Loss of $236.5 Million, or GAAP EPS of ($2.32), Inclusive of a Noncash Goodwill Impairment Charge of $189.5 Million; Fourth Quarter Non-GAAP Adjusted Net Income1 of $12.6 Million and Non-GAAP Adjusted EPS1 of $0.12 Fourth Quarter Non-GAAP Adjusted EBITDA2 Totaled $12.3 Million and Fiscal 2024 Non-GAAP Adjusted EBITDA2 Totaled $92.4 Million AUSTIN, Texas, May 28, 2024 /PRNewswire/ -- Digital Turbine, Inc. (Nasdaq: APPS) announced financial results for the fiscal fourth quarter and fiscal year ended March 31, 2024.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
ELTP | Elite Pharmaceuticals Inc | 49 | |
NSAV | NSAV Holding Inc | 98 | |
AVXL | Anavex Life Sciences Corp | 41 | |
4 | SPZI | SPOOZ Inc | 84 |
5 | VPLM | Voip Pal Com Inc | 16 |
6 | IQST | iQSTEL Inc | 31 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 68,290.92 | -1,102.51 | -1.59% | 1.34T | 4,201,465,321 |
ETH | Ethereum | 3,830.87 | -60.74 | -1.56% | 460.73B | 3,032,181,152 |
USDT | Tether USD | 0.99891 | -0.00028 | -0.03% | 97.74B | 205,854,107 |
BNB | Binance Coin | 601.05 | -2.36 | -0.39% | 94.86B | 228,418,305 |
SOL | Solana | 169.65 | -0.400 | -0.24% | 74.85B | 1,092,927,818 |
STETH | stETH | 3,834.96 | -55.87 | -1.44% | 37.58B | 10,188,668 |
XRP | Ripple | 0.528 | -0.0057 | -1.07% | 28.8B | 261,106,911 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 958,342,458 |
DOGE | Dogecoin | 0.16484 | -0.00422 | -2.50% | 23.6B | 420,865,913 |
TONCOIN | Wrapped TON Coin | 6.48 | -0.054153 | -0.83% | 22.57B | 52,830,804 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions